Tag: GlobeNewswire

Effort builds on prior collaboration to translate high-value use cases into practical applications running on IBM quantum computers

BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) — Zapata Quantum (OTCQB: ZPTA) (“Zapata” or the “Company”) today announced it has joined the IBM Quantum Network with plans to use IBM’s world-class quantum computers with Zapata’s deep expertise in use-case discovery and application development. The Company’s effort aims to help close the quantum application gap by translating advances in quantum computing into mission-critical applications and real-world impact.

“The rapid progress IBM is making on the path to fault-tolerant quantum computing brings the quantum application gap into sharper focus,” said Sumit Kapur, CEO of Zapata Quantum. “These advances must be matched by progress in identifying, evaluating and developing the applications that will deliver real-world value. We are excited for Zapata’s Quantum Application Intelligence™ to translate organizations’ highest-mission priorities into practical quantum applications.”

“IBM’s roadmap to fault-tolerant quantum computing is one of the most credible in the industry, and superconducting qubits remain one of the most capable paths to advantage because their hardware is fast,” said Jonny Olson, VP Strategy and Co-Founder of Zapata Quantum. “Joining the IBM Quantum Network lets us better identify valuable opportunities for organizations that need the fastest systems, and then prepare those organizations for the precise moment that quantum gives them real ROI.”

Joining the IBM Quantum Network builds on a history of joint IBM and Zapata research done on early quantum devices. Zapata used IBM quantum computers in a landmark study published in Nature Biotechnology that produced experimentally validated candidates targeting KRAS and was selected as one of the journal’s Top 10 Articles of 2025.¹ Scientists from the two companies also co-authored research published in npj Quantum Information, which advanced the understanding of variational quantum factoring on a superconducting processor.²

Being part of the IBM Quantum Network also reflects Zapata’s broader strategy of working with technology leaders across the quantum and AI ecosystems. Insights from being part of the IBM Quantum Network will inform Quantum Pilot™, Zapata’s hardware-agnostic platform that helps enterprises identify, prioritize, and develop quantum applications as hardware matures.

To learn more about Zapata’s work in quantum application development, please visit the Company’s website.

1. Ghazi Vakili, M., Gorgulla, C., Snider, J. et al. Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors. Nat Biotechnol 43, 1954–1959 (2025). https://doi.org/10.1038/s41587-024-02526-3
2. Karamlou, A.H., Simon, W.A., Katabarwa, A. et al. Analyzing the performance of variational quantum factoring on a superconducting quantum processor. npj Quantum Inf 7, 156 (2021). https://doi.org/10.1038/s41534-021-00478-z

About Zapata Quantum
Zapata Quantum is a leading hardware-agnostic, pure-play quantum software company focused on accelerating quantum application development. With a portfolio of more than 60 granted and pending patents developed over seven years, Zapata supports applications across cryptography, pharmaceuticals, finance, materials discovery, defense, and more. The Company is the only organization to have participated across all technical areas of DARPA’s Quantum Benchmarking program and has worked with Fortune 500 enterprises and government agencies to translate quantum advances into real-world impact. The Company’s study demonstrating the potential of quantum-enabled drug discovery was recognized as one of Nature Biotechnology’s Top 10 Papers of 2025. Learn more at zapataquantum.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the use of IBM’s quantum computers and the potential future applications and benefits of quantum applications and prospective opportunities and value that could be generated therefrom. Forward-looking statements may be prefaced by words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “should,” “would,” “intend,” “seem,” “potential,” “appear,” “continue,” “future,” “believe,” “estimate,” “forecast,” “project,” and similar words and expressions as they relate to us, are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance, and are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, many of which are outside of our control. We caution you, therefore, against relying on any of these forward-looking statements. Our actual results may differ materially from those contemplated by the forward-looking statements for a variety of reasons, including, without limitation, our ability to identify, develop and commercialize quantum computing technologies and practical applications for such technologies, our ability to secure and maintain contracts with customers and collaborators, the state of the U.S. economy including issues caused by affordability, the risk of future inflation and uncertainty surrounding interest rates and the possibility of a recession, uncertainty surrounding and impacts arising from tariffs and developments relating thereto, our ability to attract and retain key personnel, our ability to obtain, maintain and protect intellectual property rights, the risk that software and technology infrastructure on which we depend fails to perform as designed or intended, the possibility that competitors may develop or access technology with similar or superior capabilities to our technology offerings, the possibility of adverse regulatory developments that could adversely impact us or our collaborators or the technologies on which we depend, and the risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2026, and our Prospectus filed with the SEC on August 11, 2026. Any forward-looking statement made by us in this press release speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. 

Media Contact
Taylor White
taylor@hkamarcom.com

Investor Relations Contact
Richard Land
investors@zapataquantum.com

Portage, Michigan, Oct. 06, 2026 (GLOBE NEWSWIRE) —

• Kevin Lobo to transition to Executive Chair of the Board of Directors
• Current President and COO Spencer Stiles appointed Chief Executive Officer
• Leadership transition effective January 1, 2027

Stryker (NYSE:SYK), a global leader in medical technologies, today announced that as part of a planned succession process, Kevin Lobo will transition to the role of Executive Chair of the Board of Directors, effective January 1, 2027. Spencer Stiles, currently President and Chief Operating Officer of Stryker, will succeed Lobo as Chief Executive Officer and will also be appointed as a member of the company’s Board at that time.

Lobo has led a distinguished career at Stryker spanning more than 15 years. He joined the company in 2011 as Group President, became Chief Executive Officer in October 2012 and was appointed Chair of the Board in July 2014. During his transformative 14-year tenure as CEO, Lobo significantly expanded Stryker’s portfolio and global presence and tripled annual net sales from $8.7 billion in 2012 to more than $26 billion in 2026. Under his leadership, Stryker has completed more than 60 acquisitions, including Mako, which combined pioneering robotic-arm-assisted technology with Stryker’s joint-reconstruction expertise to transform the orthopaedic industry, strengthening Stryker’s position as a diversified global leader in medical technologies. Lobo also helped shape the culture that defines Stryker today, establishing its mission to make healthcare better together with its customers, while advancing a specialized business operating model that has supported the company’s distinctive performance and growth.

“Serving as CEO of Stryker has been an incredible honor, and I am proud of all that our teams have accomplished together on behalf of our customers and the patients they serve,” said Lobo. “The Board and I have worked closely on a succession plan, and with our strong foundation in place, now is the right time for this leadership transition. Having worked alongside Spencer for many years, I have seen firsthand the qualities that define his leadership: his ability to set a clear direction, inspire people and translate strategy into strong execution. He understands what makes Stryker unique and has the judgment, experience and commitment to our mission and values to build on our momentum and lead the company forward. I look forward to working with Spencer to ensure a smooth transition and to continuing to support Stryker as Executive Chair of the Board.”

“I am honored to be named Stryker’s next CEO and grateful to the Board and Kevin for their trust in me,” said Stiles. “I have a deep appreciation for our people, our culture and the customer relationships that drive our innovation and growth. Kevin has built an extraordinary legacy and a strong foundation for the future, which I am excited to build upon as we continue executing our strategy, driving growth and advancing our mission to make healthcare better.”

Stiles is a strategic, growth-oriented and people-focused leader with a proven record of execution throughout his distinguished career at Stryker spanning nearly three decades. Since joining the company’s Endoscopy business in 1999, he has held leadership roles across nearly every Stryker business, spanning Orthopaedics, MedSurg and Neurotechnology. Before becoming President and Chief Operating Officer in January 2026, Stiles served as Group President, Orthopaedics, leading the company’s Joint Replacement and Trauma & Extremities businesses and its Digital, Robotics and Enabling Technologies organization, with additional responsibility for international regions and Stryker’s enterprise mergers and acquisitions strategy. He has also led significant portfolio initiatives, including the acquisition of Wright Medical, which enhanced Stryker’s global market position in trauma and extremities, and the separation of the company’s spinal implants business.

“This announcement is the culmination of a comprehensive, long-term succession planning process,” said Sheri McCoy, Lead Independent Director of Stryker’s Board of Directors. “Spencer is a proven leader with strategic perspective and the ability to unite teams around shared priorities. The Board is confident that he is the right leader to build upon Stryker’s momentum and guide the company’s next chapter. On behalf of the Board, I also want to recognize Kevin for his exceptional leadership and service over his tenure as CEO. Kevin has positioned Stryker to enter this transition from a place of strength. With a mission-driven culture, clear strategic direction and a strong leadership team, Stryker is poised to capture the significant opportunities ahead. We are fortunate that we will continue to benefit from his experience and perspectives as Executive Chair.”

Forward-Looking Statements
This press release contains forward-looking statements subject to the safe harbor protection provided by Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements regarding the Company’s strategy, growth prospects and opportunities, and the Company’s ability to execute on its priorities during and following the transition. These forward-looking statements involve various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such risks and uncertainties include, but are not limited to: risks associated with the transition of executive leadership and the ability of Mr. Stiles and the Company’s executive team to execute on the Company’s strategy and business plans; the Company’s ability to retain key personnel during and after the transition; and other risks listed or described from time to time in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements, except to the extent required by law.

About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts
For investor inquiries:
Nick Mead, Vice President, Investor Relations at 269-385-2600 or nick.mead@stryker.com   

For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or kim.montagnino@stryker.com

Attachments

• Spencer Stiles Infographic
• Kevin Lobo Infographic

Naples, Italy and Hamilton, Bermuda, Oct. 06, 2026 (GLOBE NEWSWIRE) — The RoyaLand Company Ltd. (the “Company” or “RoyaLand”) (OTCQB: RLNDF), a Bermuda holding company focused on creating immersive, fantasy-based royalty-themed games as well as ownership and growth of its Italian professional football club Savoia 1908 FC (“Savoia” or the “Club”), today announced Savoia’s September performance, covering the Club’s league results, its run in the Coppa Italia (“Italian Cup”), and how the month fits into Savoia’s broader plan for the season.

The Club’s Plan: Build the Foundation Now, Grow From 2027/28

Savoia’s objective for the 2026/2027 season is to build the sporting and organizational foundations needed to establish itself in Serie C and then launch the Club’s growth program starting with the 2027/28 season. September was overall in line with expectations and offered positive signs of Savoia’s ability to compete at this level.

September in the League: Four Results Without Defeat

Following two defeats in the opening league matches played in August, Savoia’s squad responded by beating Altamura 2-0 in an away game and scoring three consecutive draws against Crotone, Foggia and Casarano. These four consecutive results without defeat kept the Club in the running for a competitive first season in Serie C. That run ended with a defeat later in the month.

Coppa Italia: A Statement Win in Catania

Another highlight of September was Savoia’s 3-0 away win against Catania in the Coppa Italia Serie C, which is an annual Italian domestic knock out competition played by 60 teams. This was a significant result at a prestigious venue that kept the Club’s run in the competition alive, following an earlier away win at Casertana. Savoia is now through to the Round of 16, with its next match set for October 28 against Sorrento. The Copa Italia Serie C winner qualifies for the promotion playoff round for potential advancement to Serie B.

Savoia’s 3-0 away victory over Catania marked a statement win and a place in the next round of the Coppa Italia Serie C.

About The RoyaLand Company Ltd.

The RoyaLand Company Ltd. is a Bermuda holding company focused on creating an online and offline immersive, fantasy-based royalty-themed game called TheRoyal.Land as well as mobile and other games, and ownership and growth of its Italian professional football club Savoia 1908 FC. The Company is actively focused on developing what it believes to be a novel, interactive and immersive game based on a player-empowered design. This game is expected to feature proprietary digital avatars and provide opportunities to players to earn in-game reward currency, build virtual land, and own their online assets while enhancing all of these features with premium incremental in-game content. Bridging the virtual video game world and terrestrial soccer, Savoia 1908 FC has also completed a tournament season for its eSports team competing in EA Sports FC™ online matches.

TheRoyal.Land and the management and development of Savoia 1908 FC are being conducted in collaboration with the Company’s founder and CEO Prince Emanuele Filiberto di Savoia — the grandson of the last King of Italy — as well as seven other royal families and families with legal, hereditary or historically based claims to royal positions in Russia, Albania, France, Bulgaria, Yugoslavia, Lesotho (Africa), and Mecklenburg (Germany). TheRoyal.Land is intended to integrate these families’ first-hand historical perspectives to deliver an authentic and unique past-meets-future entertainment experience.

CONTACT:
investors@theroyal.land
www.TheRoyal.Land

Attachment

• Savoia’s 3-0 away victory over Catania marked a statement win and a place in the next round of the Coppa Italia Serie C.

Tuesday, Oct. 27, 2026 at 4:30 p.m. Eastern Time

FREMONT, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company, announced today that it will host a conference call and webcast on Tuesday, Oct. 27, 2026 at 4:30 p.m. Eastern Time to discuss its third quarter 2026 financial results for the period ended Sept. 30, 2026. The live webcast can be accessed on the Enphase Energy Investor Relations website at investor.enphase.com, and a recorded version of the call will also be available there approximately one hour after the call.

What:	Enphase Energy’s Third Quarter 2026 Financial Results Earnings Conference Call and Webcast
Date:	Tuesday, Oct. 27, 2026
Time:	4:30 p.m. Eastern Time
Live Call:	833.634.5018
International:	+1.412.902.4214
Replay:	United States/Canada: 855.669.9658
	International: +1.412.317.0088
	Replay access code: 5536681

About Enphase Energy, Inc.

Enphase Energy is a global energy technology company advancing intelligent power systems for homes, businesses, and next-generation AI data centers. The company designs semiconductor-based energy technologies spanning solar, batteries, EV charging, energy management, and virtual power plants, and is developing solid-state transformer technology to address the rapidly growing power demands of AI data centers. Based in Fremont, California, Enphase is the world’s leading supplier of microinverter-based solar and battery systems. The company revolutionized the solar industry with its microinverter technology and has shipped approximately 89.4 million microinverters, with approximately 5.3 million Enphase-based systems deployed in more than 165 countries. Enphase products enable people to harness the sun to make, use, save, and sell their own power, all controlled through the Enphase App. For more information, visit https://enphase.com/.

©2026 Enphase Energy, Inc. All rights reserved. Enphase Energy, Enphase, the “e” logo, IQ, and certain other marks listed at https://enphase.com/trademark-usage-guidelines are trademarks or service marks of Enphase Energy, Inc. Other names are for informational purposes and may be trademarks of their respective owners.

Contact:

Zach Freedman
Enphase Energy, Inc.
Investor Relations
ir@enphaseenergy.com

Veteran oncology leader to oversee nursing and laboratory services and advance clinical quality and professional development across the network

FORT MYERS, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) — American Oncology Network (AON), one of the nation’s fastest-growing networks of community oncology practices, today announced the promotion of Tena Messer to chief clinical officer.

In her new role, Messer provides strategic leadership for nursing and laboratory services across AON, with a focus on advancing clinical quality, strengthening professional development and building the infrastructure and resources that support clinical teams throughout the network.

“Tena, who has been an operations executive at AON for nearly seven years, has a deep understanding of community oncology and a strong commitment to supporting the clinicians who care for our patients every day,” said Todd Schonherz, chief executive officer of AON. “Her leadership will continue to be instrumental as we strengthen our clinical programs, invest in our teams and ensure our practices have the resources they need to deliver high-quality, patient-centered cancer care.”

As president of AON’s network operations, Ella Friedman works closely with the network’s clinical and operational leaders to strengthen practice performance and support the delivery of high-quality care across the network.

“Tena understands both the clinical realities of caring for patients and the operational support our teams need to do their best work,” Friedman said. “She is a thoughtful, collaborative leader who consistently keeps patients at the center of every decision. As AON continues to grow, her leadership remains critical to strengthening our clinical infrastructure while supporting the exceptional, personalized care our practices provide in their communities.”

A key priority for Messer is expanding professional development opportunities for AON’s nursing teams. Her work includes strengthening oncology education and onboarding while creating opportunities for continued learning as cancer treatments, technologies and care delivery models evolve.

Messer will also collaborate closely with AON’s Strategic Operations and Innovation Lab teams, led by Puneeth Indurlal, executive vice president of strategic operations and enterprise solutions, to identify opportunities to improve clinical workflows, optimize resources and reduce administrative burdens. Their work includes exploring how data, automation and artificial intelligence can better support clinicians and give them more time to focus on patient care.

“Tena and I share a common goal: making sure innovation translates into meaningful improvements for the people delivering care and the patients they serve,” Indurlal said. “By bringing together her clinical expertise with our work in strategic operations, data and technology, we can identify practical solutions that reduce unnecessary administrative work, improve workflows and help our clinical teams work more effectively.”

“Our nurses and clinical teams are at the heart of the care we provide,” Messer said. “I want to make sure they have the education, resources and tools they need to grow professionally and continue providing exceptional care. As oncology continues to evolve, we also have an opportunity to thoughtfully use technology and innovation to make their work easier and give them more time to focus on the reason they do what they do: their commitment to our patients.”

Messer brings 30 years of oncology experience to the role, including work as an oncology nurse and nurse practitioner in inpatient and outpatient settings. Throughout her career, she has led clinical quality initiatives, practice certifications and the development of outpatient programs focused on survivorship, oncology triage and palliative care.

Messer earned a Master of Science in nursing and an adult medicine nurse practitioner certificate with subspecialty training in oncology and HIV from Duke University School of Nursing. She also completed the Clinical Leadership Fellowship through CTI Leadership.

As chief clinical officer, Messer will work across AON to further connect clinical expertise, operational strategy and innovation while strengthening the clinical infrastructure that supports AON’s growing network of community oncology practices.

About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 350 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6e40fa2e-a0d6-4716-a5b0-3b96b3017184

CONTACT: Media Contact:
Karen Riley Sawyer
American Oncology Network
Karen.Sawyer@AONcology.com

The competitive and esteemed award highlights Tri Pointe for fostering a welcoming workplace culture, expanding career pathways, and providing the support and development team members need to thrive

INCLINE VILLAGE, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) — Tri Pointe Homes^®, one of the largest homebuilders in the U.S., announced today that it has been selected for the 2026 Fortune Best Workplaces in Construction™ List by Great Place To Work^® and Fortune, marking the fifth consecutive year the company has earned the prestigious recognition. The distinction reflects Tri Pointe’s continued commitment to fostering a workplace where team members feel welcomed, supported, and empowered to grow while contributing to meaningful work across the homebuilding industry.

The Best Workplaces in Construction award is based on analysis of survey responses from more than 64,000 employees at Great Place To Work Certified™ companies in the construction industry. The highly competitive selection process celebrates companies that offer positive outcomes for their team members regardless of job role, race, gender, sexual orientation, or other demographic identifiers. Selection is based solely on employee feedback, providing a direct reflection of team members’ experiences within their workplace.

“Receiving this honor for a fifth consecutive year is a proud moment for Tri Pointe Homes because it’s the direct result of our team members, their experiences, and the company culture we strive to create,” said Heather Breidenthal, Chief Human Resources Officer of Tri Pointe Homes. “In 2026, 97% of team members said they felt welcomed when they joined the company, and 95% said they were made to feel right at home when changing jobs or work units. Those results speak to the culture our teams create every day and to our shared H.E.A.R.T. values of Humility, Empowerment, Authenticity, Results, and Team.”

Tri Pointe Homes continues to expand pathways into homebuilding and construction through college recruiting, internship programs, military recruitment partnerships, and its Cornerstone Club – a network of internal ambassadors who help guide and enhance recruiting, development, and mentoring efforts. Once hired, team members have access to resources designed to strengthen both professional development and connection across the company, including role-specific onboarding and learning programs that help new hires build the knowledge, relationships, and confidence needed to succeed.

The company also invests in opportunities for collaboration and development across disciplines and career stages. Initiatives such as its Area Construction Manager training program, National Safety Committee, and collaborative frame walks bring team members together to share expertise, reinforce quality and safety standards, strengthen field leadership and coaching capability, and align the cross-functional teams involved in delivering homes and communities.

The recognition among Fortune’s Best Workplaces in Construction™ list highlights Tri Pointe’s exceptional workplace culture within the construction industry. Great Place To Work, the global authority on workplace culture, determines its lists using its proprietary Trust Index™ Survey, which evaluates key factors including trust in management, connection with colleagues, and loyalty to the company. The companies that rank highest on this list are those where a broad set of employees across all demographics and roles report consistently positive workplace experiences. The highly competitive list is based on more than 1.3 million survey responses and data from companies representing more than 7.3 million employees. Honorees are selected based on their ability to provide consistently positive workplace experiences for employees across roles, work status, and demographic groups.

“A strong workplace culture is what makes great execution possible,” said Tri Pointe Homes President and Chief Operating Officer Tom Mitchell. “When people feel welcomed, supported, and trusted to do meaningful work, they bring more energy, ideas, and accountability to everything they do. That has a direct impact on how we collaborate, how we build, and ultimately, on the experience we create for our customers. Being recognized for a fifth consecutive year reinforces that investing in our people continues to be one of the most important investments we can make.”

Tri Pointe Homes continues to be a leader in fostering a workplace where team members can develop professionally, prioritize their wellbeing, and contribute to a shared sense of purpose. Through professional development, wellness resources, career pathways, community involvement, and a commitment to inclusion and belonging, the company works to create an environment in which team members feel supported and inspired throughout their careers.

For more information about Tri Pointe Homes and its award-winning culture, visit TriPointeHomes.com.

About Tri Pointe Homes^® 
One of the largest homebuilders in the U.S., Tri Pointe Homes, Inc. has a presence in 13 states and the District of Columbia, and is a recognized leader in customer experience, innovative design, and environmentally responsible business practices. The company builds premium homes and communities with deep ties to the communities it serves—some for as long as a century. Tri Pointe Homes combines the financial resources, technology platforms and proven leadership of a national organization with the regional insights, longstanding community connections and agility of empowered local teams. The company is one of the 2026 Fortune World’s Most Admired Companies, 2026 Fortune 100 Best Companies to Work For^®, and recognized as a PEOPLE Companies That Care^® (2023-2026) organization. The company was also named a Great Place To Work-Certified™ company for five years in a row and named on several Great Place To Work^® Best Workplaces lists. Tri Pointe has also won multiple Builder of the Year and Developer of the Year awards. For more information, visit TriPointeHomes.com.

About the Fortune Best Workplaces in Construction List
Great Place To Work selected the Fortune Best Workplaces in Construction by analyzing confidential survey responses from over 1.3 million employees, representing the experience of 7.3 million employees in the U.S. in 2025 and 2026. Of those responses, over 64,000 came from employees at Great Place To Work Certified companies in the construction industry, and these rankings are based on that feedback. Companies with 10 to 999 employees competed in the small and medium category. Companies with 1,000 or more employees were considered for the large category. Read the full methodology.
To get on this list next year, start here.

About Great Place To Work
As the global authority on workplace culture, Great Place To Work, a UKG company, brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Its proprietary platform and Great Place To Work Model help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified and receiving recognition on a coveted Best Workplaces list.
Follow Great Place To Work on LinkedIn, X, and Instagram, and sign up for the Great Place To Work LinkedIn newsletter, Culture Edge, to get the latest research on what drives business success.

About Fortune Media
Fortune is a global multi-platform media company built on a legacy of trusted, award-winning reporting and information for those who want to make business better. Independently owned, Fortune tells the stories of the world’s biggest companies and their leaders as well as a new generation of innovators who are moving business forward. Digitally and in print, Fortune measures corporate performance through rigorous benchmarks, and holds companies accountable, in regions around the world. Its iconic rankings include Fortune 500, Fortune Global 500, Most Powerful Women, and World’s Most Admired Companies. Fortune builds world-class communities by convening industry thought leaders for exclusive summits and conferences, including the Fortune Global Forum, Fortune Brainstorm Tech, and Fortune Most Powerful Women. For more information, visit fortune.com.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/c0f5a407-ebf0-4901-b98b-682ac892eaad
https://www.globenewswire.com/NewsRoom/AttachmentNg/f3f1d3c7-6645-4284-bf39-1e35a20e139d

CONTACT: CONTACT:
Katy Biggerstaff
kbiggerstaff@newgroundco.com / 562.761.6338

TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 06, 2026 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd., a Taiwan registered company (“EG BioMed”), officially launched the AI Cancer Risk Assessment (the “Assessment”), an online assessment that organizes an individual’s self-reported health information into a personalized report in English and Chinese, covering ten cancer types with promotional pricing of US$10.

The Assessment is based on a 52-question health survey covering personal and family history, symptoms, lifestyle, environmental exposures and diet. The survey takes approximately ten minutes, with a personalized report generated shortly after completion. The report provides low, moderate or high risk stratification overall and for each of ten cancer types: breast, colorectal, lung, head and neck, pancreatic, liver, endometrial, prostate, biliary tract and gastric cancer. It identifies the factors that contributed most to each result, explains why they may be relevant, and includes screening information and personalized follow-up guidance. The Assessment requires no blood draw, imaging or a clinic visit.

Assessment Methodology and Report

Responses are processed by a 48-feature pan-cancer model and ten cancer-specific models, together with a separate rule layer built from published clinical literature. This rule layer draws on more than 140 primary research studies and over 300 traceable risk estimates, with each rule tied to a source study and reported measure. The report includes the rules triggered by the user’s responses, their bases and references to the underlying medical literature.

Results are presented against the population baseline of the country the respondent selects, using age-standardized incidence rates. The accompanying screening information also reflects guidance issued by a particular country, as applicable (currently, the United States, Canada and Taiwan). Where a country has no national recommendation for a given cancer, the report says so rather than substituting another country’s advice.

Integration with the Companies’ Oncology Services

The Assessment sits upstream of the companies’ laboratory and clinical services. EG BioMed US Inc. (“EG BioMed US”) operates a CLIA-certified and CAP-accredited laboratory in Bothell, Washington, offering DNA methylation–based oncology tests as laboratory-developed tests. Its operational footprint spans 47 U.S. states, Washington, D.C., Guam, the U.S. Virgin Islands and American Samoa. In March 2026, YD Bio and EG BioMed launched a nationwide telehealth platform to support decentralized access to such services.

For individuals whose Assessment indicates a denser cluster of risk factors associated with certain cancer types, the report may reference the availability of related blood tests for discussion with a physician. Whether any test is appropriate remains a decision for a licensed physician.

“Understanding personal health risk factors can be a useful starting point for more informed discussions with healthcare professionals,” said Dr. Ethan Shen, Founder, Chairman and Chief Executive Officer of YD Bio. “This Assessment brings self-reported health information and published research together in a structured, personalized report. As part of our broader oncology platform, we believe it can help individuals better understand their risk factors and discuss appropriate next steps with their physicians.”

The AI Cancer Risk Assessment is available now in English and Chinese at mdi.eg-bio.com/product/ai-cancer-risk-assessment. During the promotional period, the Assessment is offered at US$10, reduced from its regular price of US$50.

Important Disclosure about the Assessment

The AI Cancer Risk Assessment is a cancer risk-stratification and health guidance tool. It uses statistical and artificial intelligence methods applied to health information self-reported by the user. Its output does not represent the probability of developing cancer. It does not diagnose cancer and is not intended for cancer diagnosis, screening, early detection, disease prediction or treatment decision-making; it cannot replace professional medical evaluation, diagnostic testing or consultation with a qualified healthcare provider.

About EG BioMed

EG BioMed is a biotechnology and clinical services company focused on advancing early cancer detection and diagnostic solutions. YD Bio entered into a Memorandum of Understanding to merge with EG BioMed in January 2026 and is advancing the transaction, which is anticipated to close in 2026, subject to customary closing conditions, regulatory approvals, and the finalization of definitive agreements.

EG BioMed US is the U.S. clinical-laboratory subsidiary of EG BioMed and operates a CLIA-certified, CAP-accredited clinical laboratory in Bothell, Washington, focused on DNA methylation–based early cancer detection and AI-driven biomarker analytics. EG BioMed and EG BioMed US are affiliates of YD Bio.

About YD Bio Limited

YD Bio is a U.S.-anchored public biotechnology company building an integrated healthcare platform spanning regulated molecular diagnostics, clinical services, precision medicine, and life science commercialization. The Company operates DNA methylation–based oncology testing programs in the United States under a laboratory-developed test strategy and supports pharmaceutical and biotechnology partners through compliant life science distribution and clinical trial supply chain services. In addition, the Company maintains regulated ocular health commercialization operations and a consumer health distribution platform in Asia. For more information, visit ir.ydesgroup.com and follow the Company on Facebook, X, Threads, Instagram and LinkedIn.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions created by the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s plans, objectives and expectations for its business, strategy, operations, and certain on-going transactions, and the potential benefit of the Assessment and any synergies with its other oncology services. Forward-looking statements are not guarantees of future performance and can be identified by words such as “aim,” “intend,” “seek,” “believe,” “designed to,” “expects,” “anticipates,” “plans,” “may,” “could,” “will” and other similar expressions. Actual results may differ materially from those expressed or implied due to a variety of factors, including consumer demand and market acceptance; competition; regulatory and labeling requirements in Taiwan and other jurisdictions; currency exchange rates; geopolitical tensions and macroeconomic conditions; and other risks and uncertainties described in YD Bio’s filings with the U.S. Securities and Exchange Commission. The Company cautions investors not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update any forward-looking statement, except as required by law, and encourages investors to review the risk factors in its Annual Report on Form 20-F and other SEC filings.

For investor and media inquiries, please contact:
YD Bio Limited
Investor Relations
Email: investor@ydesgroup.com

WFS Investor Relations Inc.
Email: services@wfsir.com
Phone: +1 628 283 9214

Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies

TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026. Ms. Hamill brings more than 35 years of global commercial, market access and business leadership experience across multiple therapeutic areas. She succeeds Yonatan Malca, who is stepping down from the Board.

“I am delighted to welcome Laura to our Board as Entera enters an important new chapter of late-stage clinical execution, commercial preparedness for EB613 and advancement of our broader pipeline,” said Miranda Toledano, Chief Executive Officer of Entera. “Laura is an exceptional leader with vast experience stewarding multi-billion dollar global therapeutic franchises. Her perspective will be invaluable as we think strategically about the potential of EB613 and our oral peptide platform.” “I would also like to express my sincere gratitude to Yonatan for his 16 years of dedicated service to Entera,” Ms. Toledano continued. “His leadership and commitment have helped guide the Company from its inception through a period of meaningful growth and transformation.”

“Entera has built a unique oral peptide pipeline with the potential to transform how important therapies are delivered to patients,” said Ms. Hamill. “I am particularly inspired by the potential of EB613 in osteoporosis and the opportunity to help millions of women preserve their bone health and maintain active, vibrant lives. I am excited to join the Board at this important stage and support Entera as it works to advance EB613 and realize the broader potential of Entera’s oral peptide platform.”

Ms. Hamill is a seasoned biopharmaceutical executive with more than 35 years of global commercial leadership experience spanning product launches, global franchise development, market access and payer strategy. Most recently, she served as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc., where she led an organization of approximately 2,500 employees responsible for $22 billion in annual revenue and oversaw the transformation of the company’s global commercial operations. Prior to Gilead, Ms. Hamill spent nearly two decades at Amgen Inc. in leadership roles of increasing scope. As Senior Vice President of U.S. Commercial Business Operations, she led commercial activities and supporting functions across Amgen’s therapeutic areas, representing approximately 80% of Amgen’s revenue. She previously served as Senior Vice President of Amgen’s Intercontinental Region, overseeing 26 countries worldwide. Earlier in her Amgen career, she held leadership roles including Vice President of International Marketing and Business Operations in Switzerland and Vice President of U.S. Corporate Accounts and Reimbursement. Ms. Hamill currently serves on the Boards of Directors of Jazz Pharmaceuticals plc (Nasdaq: JAZZ), BB Biotech AG and Fate Therapeutics, Inc. (Nasdaq: FATE). She previously served on the boards of Acceleron Pharma Inc., Pardes Biosciences and Y-mAbs Therapeutics, Inc. Ms. Hamill holds a Bachelor of Business Administration in Marketing from the University of Arizona.

About Entera
Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages a disruptive and proprietary technology platform (N-Tab®) and its pipeline of first-in-class oral peptide programs. The Company’s most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet for osteoporosis. A placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n = 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is also developing the first oral Long Acting PTH(1-34) tablet as a replacement therapy for patients with hypoparathyroidism (EB612), the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide tablet for the treatment of obesity and metabolic syndromes; and the first oral GLP-2 tablet as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health, Inc. For more information on Entera, visit www.enterabio.com or follow us on LinkedIn, Twitter, and Facebook.

Cautionary Statement Regarding Forward Looking Statements
Various statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy, clinical development activities, collaboration arrangements and expected financial and operational results are forward-looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera’s forward-looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s ability to establish and maintain development and commercialization collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statement Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10-K filed with the SEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward-looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward-looking statements Entera makes in this press release. The information in this press release is provided only as of the date of this press release, and Entera undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

Company Contact:
IR@enterabio.com

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that it will host an in-person and virtual R&D Day on Tuesday, October 27, 2026, with presentations beginning at 2:00 PM ET and a reception to follow. The event will feature Roger S. McIntyre, MD, FRCPC (University of Toronto), alongside LB management team members Heather Turner (CEO), Susan G. Kozauer (CMO), Kaya Pai Panandiker (CCO), Gad Soffer (COBO), and Joe Miller (CFO), as the Company looks ahead to its upcoming topline Phase 3 data readout in schizophrenia. To register, click here.

LB-102 is a novel, investigational, once-daily oral selective antagonist of D2, D3 and 5HT7 receptors with a unique bimodal mechanism. It is being developed by LB Pharma for the treatment of schizophrenia, bipolar depression, the adjunctive treatment of major depressive disorder, as well as other neuropsychiatric disorders, and has the potential to be the first therapy with this unique mechanism approved for neuropsychiatric disorders in the United States.

Topics will include:

• New scientific insights on LB-102’s unique mechanism of action that underlies the emerging clinical profile and potential opportunity across a wide variety of brain disorders
• Discussion of the Phase 3 trial program in schizophrenia, its upcoming topline data readout expected in the first half of 2027, and ongoing pre-commercial planning activities

A live question and answer session will follow the formal presentations.

About Roger S. McIntyre, MD, FRCPC
Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto. For a decade, he was recognized by Clarivate Analytics one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre has authored/co-authored more than 1200 articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders.

His research focuses primarily on characterizing the phenomenology and neurobiology of mood disorders and advancing novel therapeutics. He has been especially interested in identifying innovative, rapid acting psychotropic treatments for mood disorders, and his research has also extended into public health and implementation research at the population-based level.

Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.

About LB-102
LB-102 is a novel, once-daily, orally administered investigational small molecule being developed for multiple neuropsychiatric disorders.  It is a new chemical entity that has been structurally engineered with a modification to amisulpride, a widely used antipsychotic outside the United States, and has the potential to be the first benzamide antipsychotic in the United States for the treatment of neuropsychiatric disorders. LB-102 was developed with the aim of retaining amisulpride’s benefits while addressing its limitations. LB-102 is a potent and selective antagonist of D2, D3, and 5-HT7 receptors with few off-target effects and which may have broad therapeutic potential across psychosis and mood disorders. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. In this trial, LB-102 demonstrated statistically significant benefit versus placebo at all doses studied, including rapid onset of effect at week 1 and sustained benefit through the endpoint of the trial, a potentially class-leading safety profile with low rates of EPS (including akathisia), minimal sedation and few GI side effects, alongside effects on negative symptoms and cognitive performance. These data underscore LB-102’s potential to address multiple dimensions of neuropsychiatric illness. The pivotal Phase 3 NOVA-2 trial of LB-102 for acute schizophrenia and the Phase 2 ILLUMINATE-1 trial of LB-102 for bipolar 1 depression are ongoing, and a Phase 2 trial of LB-102 in adjunctive treatment of MDD is planned. The Company is also pursuing additional expansion opportunities for LB-102 including predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as other neuropsychiatric diseases. 

About LB Pharmaceuticals

LB Pharmaceuticals is a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the therapeutic benefits of LB-102; and the expected topline results from the Phase 3 NOVA-2 trial. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

These and other risks are described more fully in the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and its other documents to be subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media and Investor Contact:
Ellen Rose
erose@lbpharma.us

Additional poster presentations highlight Vafseo® (vadadustat) clinical and economic data

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced upcoming presentations at the American Society of Nephrology Kidney Week 2026 (ASN Kidney Week), which will take place in Denver, CO from October 21-25, 2026. U.S. Renal Care will present the results of the VOICE trial evaluating the safety of three-times-weekly vadadustat compared with an erythropoiesis-stimulating agent (ESA) in patients receiving in-center hemodialysis as a late-breaking presentation. Additionally, Akebia will have multiple poster presentations featuring its rare kidney disease pipeline, including a poster highlighting preclinical research of praliciguat in focal segmental glomerulosclerosis (FSGS), the Phase 2 trial evaluating praliciguat in FSGS, and the Phase 2 basket trial of ebribafusp alfa in complement-mediated kidney diseases. Akebia will also present posters evaluating clinical and economic outcomes associated with Vafseo® (vadadustat).

ASN Kidney Week attendees can visit Akebia at Booth #682 in the Exhibit Hall.

Late-breaking presentation by U.S. Renal Care details:

Vadadustat Three Times Weekly for the Treatment of Anemia in Patients Receiving Hemodialysis
Presenter: Geoffrey A. Block, M.D., FASN, Associate Chief Medical Officer and Senior Vice President, Clinical Research & Medical Affairs for U.S. Renal Care
Date and Time: October 23, 2026; 12:00 to 12:15 PM MT

Akebia-supported posters to be presented in the Exhibit Hall

Posters related to rare kidney disease pipeline:

Renal-Protective Effects of Praliciguat in Preclinical Models of Focal Segmental Glomerulosclerosis
Poster #: TH-PO0380
Date and Time: October 22, 2026; 10:00 AM to 12:00 PM MT

A Phase 2 Trial of Praliciguat Therapy in Patients with FSGS
Poster #: INFO18-SA
Date and Time: October 24, 2026; 10:00 AM to 12:00 PM MT

Tissue-Targeted Complement Inhibition in Rare Kidney Disease: A Phase 2 Open-Label Basket Trial of Ebribafusp Alfa
Poster #: INFO12-SA
Date and Time: October 24, 2026; 10:00 AM to 12:00 PM MT

Posters related to Vafseo® (vadadustat):

Cost Analysis of Hospitalizations for Vadadustat vs. Darbepoetin Alfa Based on the Phase 3 INNO₂VATE Trials
Poster #: FR-PO0609
Date and Time: October 23, 2026; 10:00 AM to 12:00 PM MT

Comparison of Major Adverse Cardiovascular Events with Once-Daily vs. Three-Times-Weekly Vadadustat Dosing in Patients with Dialysis-Dependent CKD
Poster #: SA-PO1096
Date and Time: October 24, 2026; 10:00 AM to 12:00 PM

Comparison Between Vadadustat Exposure (Cmax) and Major Adverse Cardiovascular Events in Patients with Dialysis-Dependent CKD
Poster #: SA-PO1097
Date and Time: October 24, 2026; 10:00 AM to 12:00 PM MT

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Waltham, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

About Vafseo® (vadadustat) tablets
Vafseo® (vadadustat) tablets is a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin, increasing hemoglobin and red blood cell production to manage anemia. Vafseo is approved for use in 37 countries.

INDICATION
VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.

Limitations of Use

• VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being.
• VAFSEO is not indicated for use:
  • As a substitute for red blood cell transfusions in patients who require immediate correction of anemia.
  • In patients with anemia due to CKD not on dialysis.

IMPORTANT SAFETY INFORMATION about VAFSEO (vadadustat) tablets

WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, and THROMBOSIS OF VASCULAR ACCESS.

VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE).

Targeting a hemoglobin level greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events, as occurs with erythropoietin stimulating agents (ESAs), which also increase erythropoietin levels.

No trial has identified a hemoglobin target level, dose of VAFSEO, or dosing strategy that does not increase these risks.

Use the lowest dose of VAFSEO sufficient to reduce the need for red blood cell transfusions.

CONTRAINDICATIONS

• Known hypersensitivity to VAFSEO or any of its components
• Uncontrolled hypertension

WARNINGS AND PRECAUTIONS

• Increased Risk of Death, Myocardial Infarction (MI), Stroke, Venous Thromboembolism, and Thrombosis of Vascular Access
  A rise in hemoglobin (Hb) levels greater than 1 g/dL over 2 weeks can increase these risks. Avoid in patients with a history of MI, cerebrovascular event, or acute coronary syndrome within the 3 months prior to starting VAFSEO. Targeting a Hb level of greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events. Use the lowest effective dose to reduce the need for red blood cell (RBC) transfusions. Adhere to dosing and Hb monitoring recommendations to avoid excessive erythropoiesis.

• Hepatotoxicity
  Hepatocellular injury attributed to VAFSEO was reported in less than 1% of patients, including one severe case with jaundice. Elevated serum ALT, AST, and bilirubin levels were observed in 1.8%, 1.8%, and 0.3% of CKD patients treated with VAFSEO, respectively. Measure ALT, AST, and bilirubin before treatment and monthly for the first 6 months, then as clinically indicated. Discontinue VAFSEO if ALT or AST is persistently elevated or accompanied by elevated bilirubin. Not recommended in patients with cirrhosis or active, acute liver disease.

• Hypertension
  Worsening of hypertension was reported in 14% of VAFSEO and 17% of darbepoetin alfa patients. Serious worsening of hypertension was reported in 2.7% of VAFSEO and 3% of darbepoetin alfa patients. Cases of hypertensive crisis, including hypertensive encephalopathy and seizures, have also been reported in patients receiving VAFSEO. Monitor blood pressure. Adjust anti-hypertensive therapy as needed.

• Seizures
  Seizures occurred in 1.6% of VAFSEO and 1.6% of darbepoetin alfa patients. Monitor for new-onset seizures, premonitory symptoms, or change in seizure frequency.

• Gastrointestinal (GI) Erosion
  Gastric or esophageal erosions occurred in 6.4% of VAFSEO and 5.3% of darbepoetin alfa patients. Serious GI erosions, including GI bleeding and the need for RBC transfusions, were reported in 3.4% of VAFSEO and 3.3% of darbepoetin alfa patients. Consider this risk in patients at increased risk of GI erosion. Advise patients about signs of erosions and GI bleeding and urge them to seek prompt medical care if present.

• Serious Adverse Reactions in Patients with Anemia Due to CKD and Not on Dialysis
  The safety of VAFSEO has not been established for the treatment of anemia due to CKD in adults not on dialysis and its use is not recommended in this setting. In large clinical trials in adults with anemia of CKD who were not on dialysis, an increased risk of mortality, stroke, MI, serious acute kidney injury, serious hepatic injury, and serious GI erosions was observed in patients treated with VAFSEO compared to darbepoetin alfa.

• Malignancy
  VAFSEO has not been studied and is not recommended in patients with active malignancies. Malignancies were observed in 2.2% of VAFSEO and 3.0% of darbepoetin alfa patients. No evidence of increased carcinogenicity was observed in animal studies.

ADVERSE REACTIONS

• The most common adverse reactions (occurring at ≥ 10%) were hypertension and diarrhea.

DRUG INTERACTIONS

• Iron supplements and iron-containing phosphate binders: Administer VAFSEO at least 1 hour before products containing iron.
• Non-iron-containing phosphate binders: Administer VAFSEO at least 1 hour before or 2 hours after non-iron-containing phosphate binders.
• BCRP substrates: Monitor for signs of substrate adverse reactions and consider dose reduction.
• Statins: Monitor for statin-related adverse reactions. Limit the daily dose of simvastatin to 20 mg and rosuvastatin to 5 mg.

USE IN SPECIFIC POPULATIONS

• Pregnancy: May cause fetal harm. A pregnancy exposure registry is available to monitor outcomes in women exposed to VAFSEO during pregnancy. Report pregnancies to 1-844-445-3799.
• Lactation: Breastfeeding not recommended until two days after the final dose.
• Hepatic Impairment: Not recommended in patients with cirrhosis or active, acute liver disease.

Please note that this information is not comprehensive. Please click here for the Full Prescribing Information, including BOXED WARNING and Medication Guide.

Akebia Therapeutics® and Vafseo® are registered trademarks of Akebia Therapeutics, Inc.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com